Normal saline (Placebo); botulinum toxin Type A (200U)

OTHER3 trials

Sponsors

Allergan

Conditions

Overactive Bladder

Phase 2

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

TerminatedNCT00575016

AllerganOveractive Bladder

Start: 2007-12-31End: 2010-07-31Updated: 2015-10-02

Phase 3

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

CompletedNCT00311376

AllerganOveractive Bladder

Start: 2006-08-31End: 2010-05-31Updated: 2015-12-04

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

CompletedNCT00461292

AllerganOveractive Bladder

Start: 2007-05-31End: 2010-04-30Updated: 2015-10-02

Related Papers

Development of the Incontinence Utility Index: estimating population-based utilities associated with urinary problems from the Incontinence Quality of Life Questionnaire and Neurogenic Module.

2014-10-089 citations

OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity.

2013-07-2631 citations

Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

2011-07-13317 citations